Autolus Therapeutics PLC (AUTL) Actualités

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations...

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

LONDON, May 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Form 8-K - Current report

Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call

LONDON, May 13, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL

Submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in r/r B-ALLThe US marketing...

Autolus Therapeutics Announces Changes to its Board of Directors

LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Announced strategic collaboration and equity investment from BioNTech for aggregate proceeds of $250 million...

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

LONDON, March 12, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...

Autolus Therapeutics announces publication in Blood Cancer Journal

LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...